Frontage Holdings Corporation, a contract research organization (CRO) providing integrated, science-driven research and development services with presence in both North America and China, has acquired ACME Bioscience through its subsidiary Frontage Laboratories, Inc.
 
ACME provides discovery chemistry, medicinal chemistry, process chemistry research and development, and chemical manufacturing services for worldwide biopharmaceutical companies. ACME has extensive experience in antiviral and anti-bacterial research, along with expertise in nucleotides, nucleosides, triphosphates pro-drugs, heterocycles, and boron containing compounds, and has partnered with many customers in developing new chemical entities. 
 
“It has been one of our strategies and the ultimate goal to expand the range of the services to our customers with more integrated solutions through organic growth and potential acquisitions,” said Song Li, founder and honorary chairman of the Group and CEO of Frontage Labs. “This acquisition will extend our capabilities of organic synthesis, medicinal chemistry, and process research and development, and will enable us to capture growth in the drug discovery and early stage development and other ancillary services, which can also strengthen Frontage’s position to provide more comprehensive and high-quality services to our customers in North America, Asia, and Europe.”
 
Jason Zhang, founder and CEO, Acme Bioscience, said, “Acme Bioscience has provided exceptional chemistry services to biotech and pharmaceutical communities for the past twenty years. Through Frontage Labs’ acquisition, we will be able to fulfil the essential part of the drug discovery process for small organic molecules. Thus, by combining the expertise of both companies, we will be able to expand the services we provide to our customers.”